ABSTRACT
Background: Acute myeloid leukemia (AML) is the most common leukemia in adults. Aim: To Describe our population of patients with AML and report the outcomes of our treatments. Material and Methods: Review of electronic clinical records of 114 patients with AML with a median age of 57 years (59% men). Results: Seventeen percent of patients were classified as low risk, 38% as intermediate risk and 33% as high risk. Seventy-six percent of patients were treated with intensive chemotherapy. Five years overall survival according to cytogenetic risk was 59, 41, and 12% in low, intermediate, and high-risk patients, respectively. The outcomes were better in patients under 60 years. The median survival of patients treated with intensive chemotherapy aged less than 60 years and 60 years and above was 3.4 and 1 year, respectively. Conclusions: Our results are comparable to those reported in developed countries. Improving the survival of patients 60 years and older is our main challenge.
ABSTRACT
Background: In our country, transplantation centers differ in the age limit for allogeneic hematopoietic transplantation (ALOHT). In our program, transplants with age- adjusted conditioning are performed in patients until 70 years old. Currently more than 60% of ALOHT reported to the Center for International Bone Marrow Transplantation Research (CIBMTR) are performed in patients older than 40 years. Aim: To report our experience with ALOHT in acute myelogenous leukemia (AML), analyzing patient age at transplantation in different periods and transplant results in different age groups. Material and Methods: A retrospective analysis of the database of adult hematopoietic transplants in AML patients was performed. Demographic data, disease characteristics, transplant data, survival and relapse times, and mortality were collected. Results: In our program, 1030 transplants were performed in adults and 119 ALOHT were performed in AML patients, between 1990 and 2020. The median age of patients in all periods was 41 years, (range 16-69). The median age was 33 and 45 years, in the periods 1990-2000 and 2000-2020 respectively (p < 0.01). Seventy-eight patients received myeloablative conditioning (median age 44 years) and 41 reduced intensity conditioning (median age 53 years). Five-year overall survival was 44.6% (confidence intervals (CI) 41-48). Non relapse mortality of all periods was 19% (CI 17 - 40%) and relapse rate was 17 % (CI 16-22). No difference in five years overall survival among patients younger than 40, 41 to 50 and over 51 years was observed. Conclusions: Overall Survival, non-relapse mortality and relapse rate were similar in younger and older patients in our program and similar to those previously reported in other centers.
ABSTRACT
Los tumores de tejido cromafín, hormonalmente activos y capaces de producir daño a varios órganos e incluso la muerte, con frecuencia permanecen insospechados ejerciendo por períodos prolongados su efecto deletéreo. Con frecuencia son múltiples y al problema de su diagnóstico se agrega el de su localización. Describimos el caso de una mujer joven, con historia de episodios paroxísticos de palpitaciones, disnea, opresión precordial e hipertensión arterial de ocho años de evolución. El diagnóstico de tumor cromafín fue realizado a través de determinación de catecolaminas séricas y urinarias. Fué intervenida quirúrgicamente en tres ocasiones después de efectuar ultrasonografía de abdomen y pelvis, tomografía axial computada de torax, abdomen y pelvis, muestreo hormonal a través de cavografía; arteriografía selectiva y empleo de metaiodo-benzyl-guanidina 131. Enfatizamos la incapacidad de los métodos empleados, cruentos e incruentos y la ausencia del procedimiento ideal cuando se emplean aisladamente. Recomendamos también el estudio de la respuesta presora al ejercicio en banda sinfín para evaluar el comportamiento de las resistencias periféricas en sí, una vez conseguida la curación quirúrgica